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Abstract
The granulocyte colony-stimulating factor receptor (G-CSFR) is a critical regulator of granulopoiesis. Mutations in the G-CSFR
in patients with severe congenital neutropenia (SCN) transforming to acute myelogenous leukemia (AML) have been shown
to induce hypersensitivity and enhanced growth responses to G-CSF. Recent studies have demonstrated the importance of
the ubiquitin/proteasome system in the initiation of negative signaling by the G-CSFR. To further investigate the role of
ubiquitination in regulating G-CSFR signaling, we generated a mutant form of the G-CSFR (K762R/G-CSFR) which abrogates
the attachment of ubiquitin to the lysine residue at position 762 of the G-CSFR that is deleted in the D716 G-CSFR form
isolated from patients with SCN/AML. In response to G-CSF, mono-/polyubiquitination of the G-CSFR was impaired in cells
expressing the mutant K762R/G-CSFR compared to cells transfected with the WT G-CSFR. Cells stably transfected with the
K762R/G-CSFR displayed a higher proliferation rate, increased sensitivity to G-CSF, and enhanced survival following cytokine
depletion, similar to previously published data with the D716 G-CSFR mutant. Activation of the signaling molecules Stat5
and Akt were also increased in K762R/G-CSFR transfected cells in response to G-CSF, and their activation remained
prolonged after G-CSF withdrawal. These results indicate that ubiquitination is required for regulation of G-CSFR-mediated
proliferation and cell survival. Mutations that disrupt G-CSFR ubiquitination at lysine 762 induce aberrant receptor signaling
and hyperproliferative responses to G-CSF, which may contribute to leukemic transformation.
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Introduction
The granulocyte colony-stimulating factor receptor (G-CSFR)
plays a critical role in myeloid cell survival, proliferation, and
neutrophilic maturation [1–8]. Like other members of the cytokine
receptor family, the G-CSFR undergoes conformational changes
in response to G-CSF binding, leading to activation of associated
Jak kinases and downstream signaling cascades that include signal
transducer and activators of transcription (Stat) kinases, Ras/
mitogen-associated protein (Ras/MAP) kinase, and the phospha-
tidylinositol-3 (PI3) kinase/Akt pathways [9–10]. Simultaneously,
mechanisms that down-regulate the G-CSFR in target cells are
rapidly turned on to attenuate receptor signaling and protect cells
from over-stimulation. Although multiple processes, including the
recruitment of SHIP and SHP-1 to the G-CSFR complex as well
as the production of SOCS proteins [11–13] have been extensively
studied, the mechanisms mediating negative G-CSFR signaling
remain poorly understood.
Ligand binding has been shown to trigger intracellular signaling
as well as endocytosis, internalization, and subsequent intracellular
degradation of growth factor receptors. For the Type I cytokine
receptors to which the G-CSFR belongs, endocytosis and
degradation have been best characterized for the growth hormone
receptor (GH-R), interleukin-2 receptor (IL-2R), and the erythro-
poietin receptor (EpoR) [14–19]. These receptors all undergo
ligand-induced ubiquitination. Enzymatic attachment of ubiquitin,
a 76 amino acid polypeptide, to lysine residues present in these
receptors was shown to provide a recognition tag for delivery of
the receptors to either the lysosome or proteasome. In the acidic
environment of lysosomes, bound ligands can dissociate from their
respective receptors, while in the proteasome the ubiquitinated
receptors are degraded, processes that both culminate in
attenuation of receptor signaling.
We previously examined the role of the ubiquitin/proteasome
system in G-CSFR internalization and intracellular sorting [20].
The G-CSFR was shown to be ubiquitinated via ligand-dependent
and independent mechanisms and disruption of the ubiquitin
machinery inhibited endocytosis of the G-CSFR. Pre-treatment of
both transfected cells and primary human neutrophils with
proteasome inhibitors inhibited ligand-induced degradation of
the activated G-CSFR, indicating the importance of G-CSFR
ubiquitination and the proteasome in modulating G-CSFR surface
expression.
To further investigate the role of ubiquitination in G-CSFR-
mediated cell proliferation, we generated a mutant form of the G-
CSFR (K762R/G-CSFR) which abrogates the attachment of
ubiquitin molecules to the lysine residue at position 762 of the
receptor that is deleted by mutations in the G-CSFR in patients
with SCN/AML. In response to G-CSF, mono-/polyubiquitina-
tion was impaired in cells transiently expressing the mutant
receptor form. Cells stably transfected with the K762R/G-CSFR
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and extended cell survival following G-CSF depletion. Activa-
tion of both Stat5 and Akt were also prolonged in K762R/G-
CSFR transfected cells in response to G-CSF, and their
activation remained prolonged even after G-CSF withdrawal.
These data indicate that ubiquitination of the C-terminal lysine
in the G-CSFR that is detected in patients with SCN/AML is
required for normal G-CSFR-mediated cell proliferation and
survival.
Results
Mono-/polyubiquitination is impaired in cells transfected
with the K762R/G-CSFR
We previously reported that the WT G-CSFR undergoes
both mono- and polyubiquitination in response to G-CSF,
which could be detected using the commercially available FK2
antibody [20]. To investigate whether the K762R/G-CSFR
mutation leads to impaired ubiquitination, we transiently co-
transfected CHO cells with HA-tagged ubiquitin together with
either the wild-type or the mutant G-CSFR construct. As shown
in Figure 1A, ligand-induced mono-/polyubiquitination could
be detected in cells expressing the WT G-CSFR but not the
K762R/G-CSFR mutant. The increased ubiquitination ob-
served in cells expressing the WT G-CSFR but not the K762R
mutant could not be attributed to the levels of receptor protein
loading as demonstrated by reblotting the same blot with
antibody to V5 recognizing the V5 epitope tag fused to each
receptor form (Figure 1B). This finding indicates that the lysine
at position 762 is critical for ligand-induced ubiquitination of
the G-CSFR.
BaF3 cells expressing the K762R/G-CSFR exhibit
increased sensitivity, survival and growth to G-CSF
We previously reported that BaF3 cells transfected with the
D716 G-CSFR that is detected in a majority of patients with SCN
transforming to AML exhibit hyperproliferative responses to G-
CSF [10]. Since lysine762 localizes to the region that is deleted in
the D716 G-CSFR mutant, we were interested in investigating
whether cells expressing the K762R/G-CSFR also exhibited
ligand-induced hyperproliferative responses to G-CSF.
We stably transfected BaF3 cells with either the WT- or the
K762R/G-CSFR construct and isolated by limited dilution three
independent clones each expressing similar levels of the WT or the
K762R/G-CSFR, removed them from IL-3-containing media,
washed them, then treated them with varying concentrations of G-
CSF for a period of 72 h. As shown in Figure 2A, cells expressing
the mutant K762R/G-CSFR grew significantly better than WT
G-CSFR-expressing cells at very low concentrations of G-CSF.
The shift to the left in the dose-response curve observed with cells
expressing the K762R mutant is similar to previously published
data from our laboratory with the D716 mutant [10], indicating
that like the D716 mutant, cells expressing the K762R mutant are
also hypersensitive to G-CSF. At concentrations of G-CSF as low
as 0.08 ng/ml, all WT clones died within 10 days, with some dying
as early as 3 days, while all of the K762R clones survived for
periods exceeding 20 days (Figure 2B). We next examined the
overall growth rate of the BaF3 transfectants at a concentration of
G-CSF of 2 ng/ml, a concentration at which both WT and
K762R transfectants exhibited long-term growth. For these
experiments, the cells were washed out of IL-3, counted, seeded
at the same density of 1610
5 cells/ml, and grown in 2 ng/ml of
G-CSF for a period of 18 days. As shown in Figure 2C, K762R
clones proliferated at a higher rate than WT clones.
We next examined the survival capacity of the K762R
transfectants compared to WT transfectants following removal
from G-CSF-containing media. For these experiments, we used
pools of three independent clones of WT transfectants or K762R
transfectants and analyzed their survival following incubation in
media containing 10 ng/ml of G-CSF and subsequent transfer to
cytokine-free media. As shown in Figure 2D, using the ATP-based
CellTiter-Glo assay that measures luminescence as a correlation of
live cell numbers, K762R-expressing cells exhibited increased
survival over WT cells following G-CSF withdrawal. As a control
for the CellTiter-Glo assay, results are also shown for wells devoid
of cells and containing media alone. To confirm the observed
hypersensitivity, hyperproliferation, and prolonged survival of the
K762R transfectants was not due to differences in G-CSFR
expression levels in the BaF3 transfectants, Western blot analysis
using antibody to the V5 tag that was fused to each receptor form
was performed. As shown in Figure 2E, equivalent receptor
expression levels were detected in WT and K762R transfectants.
As an additional control, we further confirmed equivalent protein
loading by stripping the same blots and re-blotting them with
antibody to actin (Figure 2E, lower panel).
Myeloid cells expressing the K762R mutant
hyperproliferate in response to G-CSF and display
increased growth and survival
To confirm that our observations in the BaF3 lymphoid cell line
were physiologically relevant, we next examined the growth and
survival of 32D myeloid cells transfected with the K762R mutant.
As shown in Figure 3A, 32D cells expressing the K762R/G-CSFR
mutant also hyperproliferated in response to G-CSF compared to
WT G-CSFR transfectants. Like BaF3 cells transfected with the
Figure 1. Impaired mono-/polyubiquitination of the K762R/G-
CSFR in response to ligand binding. CHO ts20 cells were
transiently transfected with HA-tagged ubiquitin alone (HA only), HA-
Ubiquitin plus WT G-CSFR (HA+WT), or HA-Ubiquitin plus K762R/G-CSFR
(HA+K762R). At 48 hrs after transfection, cells were washed and
incubated in serum-free media at 4uC for 4 hrs before being transferred
to 37uC and incubated with G-CSF (100 ng/mL) for the indicated times.
Cells were then lysed, immunoprecipitated with anti-V5 antibody, and
blotted with (A) the FK2 antibody which recognizes both poly- and
monoubiquitinated proteins. (B) The blot in (A) was stripped and re-
blotted with anti-V5 antibody as a control for receptor protein loading.
doi:10.1371/journal.pone.0003422.g001
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mutant showed enhanced survival following G-CSF withdrawal
(Figure 3B).
Activation of Stat5 but not Stat3 is prolonged in cells
expressing the K762R/G-CSFR mutant
To determine the mechanisms underlying the aberrant response
of cells expressing the K762R/G-CSFR mutant to G-CSF, we
next examined the activation of Stat5 and Stat3 in these cells,
pathways known to be activated by G-CSF. For these experiments,
cells were washed out of IL-3-containing media, treated with G-
CSF for 10 min, washed, then transferred to cytokine-free media
for up to 2 h. Whole cell lysates from WT- and K762R/G-CSFR-
transfectants were then analyzed for evidence of phosphorylation
of Stat5 and Stat3 by immunoblot analysis with antibodies to
phosphor-Stat5 and phosphor-Stat3. As shown in Figure 4,
10 min after G-CSF stimulation, strong phosphorylation of Stat5
was observed in both WT and K762/G-CSFR transfectants.
Notably, strong phosphorylation of Stat5 could still be detected in
the K762R transfectants compared to WT transfectants at 1 h
after G-CSF wash-out, which could still be detected at 2 h. In
contrast, in WT cells, Stat5 phosphorylation rapidly diminished
after cytokine withdrawal, and could not be detected at 2 h
following G-CSF washout. This difference was not due to unequal
protein loading as demonstrated by stripping and immunoblotting
the same blots with antibody to Stat5 (Figure 4, lower panel). We
also examined Stat3 signaling in WT and K762R transfectants
following G-CSF stimulation then cytokine wash-out. In contrast
Figure 2. G-CSF hypersensitivity, hyperproliferation, and extended survival of transfected BaF3 cells expressing the K762R/G-CSFR
mutant. (A) WT and K762R stable transfectants were grown in varying concentrations of G-CSF for 72 h and cell numbers counted. (B) WT and
K762R stable transfectants were grown in 0.08 ng/ml of G-CSF for 20 days and cell viability determined by Trypan Blue staining. (C) Cells were grown
in 2 ng/ml of G-CSF for 18 days and cell numbers counted. (D) Pooled transfectants were washed out of IL-3, grown in 10 ng/ml of G-CSF overnight,
washed, and the viability of the cells measured over a period of 24 h using the CellTiter-Glo Luminescent Cell Viability Assay. Error bars indicating SEM
from three independent experiments are shown. (E) Expression levels of the WT or the K762R G-CSFR were analyzed by Western blotting using anti-
V5 antibody (upper panel). Untransfected parental BaF3 cells (Unt) were used as a negative control. The membrane in the upper panel was stripped
and re-blotted with anti-actin antibody to confirm equal protein loading (lower panel).
doi:10.1371/journal.pone.0003422.g002
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K762R/G-CSFR-transfected cells (Figure 5).
G-CSF-induced activation of Akt is markedly prolonged in
K762R/G-CSFR transfectants
We next investigated activation of the Akt signaling pathway in
response to G-CSF, which we have previously shown to be
important in G-CSF-mediated cell survival and proliferation. Cells
were stimulated with G-CSF for 10 min, lysed, and immunopre-
cipitated with Akt antibody, then blotted with an antibody
recognizing the phospho-serine Akt species. As shown in
Figure 6, phosphorylation of Akt on serine residues is readily
detected at 10 min following G-CSF stimulation in both WT- and
K762R/G-CSFR transfectants. Notably, phosphorylation of Akt
on serine residues was markedly prolonged in K762R mutants
compared to WT transfectants (Figure 6). Detection of pSerAkt in
WT cells was transient and undetectable by 60 min in WT cells,
whereas pSerAkt could still be strongly detected in K762R
transfectants at both 60 min and 2 h after G-CSF withdrawal.
Discussion
Receptor desensitization rapidly follows growth factor receptor
activation and serves as a mechanism for controlling the amplitude
and duration of intracellular signaling. Disruption of the delicate
balance between growth factor receptor activation and inactiva-
tion has been shown to be associated with severe human
pathologies [20]. In the case of the G-CSFR, mutations have
been identified in patients with SCN transforming to AML that
lead to prolonged receptor activation in response to G-CSF
stimulation [9,21,22]. These mutations produce C-terminal
truncated G-CSFR forms. The D716 truncated form of the G-
CSFR deletes the distal-most 98 carboxy-terminal amino acids of
the G-CSFR and is the most frequent mutation detected in
patients with SCN/AML [21–25]. Our laboratory and others
have previously shown that the mutation in the D716 G-CSFR
deletes a critical domain that mediates receptor internalization and
degradation [9,26–28]. Cells expressing the truncated G-CSFR
form exhibit increased receptor expression at the membrane
surface, which correlates with sustained intracellular activation
and enhanced growth and survival responses to G-CSF [10,29–
31].
For many receptors, ligand-induced ubiquitination has been
shown to be a crucial initial event in attenuation of receptor
signaling [32,33]. Although the cytoplasmic domain of the G-
CSFR lacks a classical ubiquitin-dependent endocytosis motif, it
Figure 3. Enhanced proliferation and viability of 32D cells
expressing the K762R/G-CSFR mutant. 32Dcl3 cells were stably
transfected with the WT G-CSFR or the K762R/G-CSFR. (A) Pooled
transfectants were grown in 2 ng/ml of G-CSF and cell numbers
determined over a period of 72 h. (B) Pooled transfectants were
washed out of IL-3, grown in 10 ng/ml of G-CSF overnight, washed, and
the viability of the cells measured using the CellTiter-Glo Luminescent
Cell Viability Assay over a period of 12 h. Error bars indicating the SEM
from three independent experiments are shown.
doi:10.1371/journal.pone.0003422.g003
Figure 4. Prolonged G-CSF-induced Stat5 activation in K762R/
G-CSFR transfectants. BaF3 cells stably transfected with either the
WT G-CSFR or K762R/G-CSFR were washed and incubated in cytokine-
free media (RPMI/0.1%BSA) at 37uC for 4 hrs. Cells were then treated
with G-CSF (100 ng/ml) at 37uC for 10 min, washed, incubated in media
depleted of growth factors for the indicated times, and lysed. Proteins
from whole cell lysates were separated on SDS-PAGE and transferred
onto nitrocellulose membranes, which were blotted with anti-phospho-
Stat5 antibody (upper panel). The blot was stripped and re-blotted with
anti-Stat5 antibody to confirm equal protein loading (lower panel). Cells
stimulated with activated orthovanadate at room temperature for
20 min are shown as a positive control.
doi:10.1371/journal.pone.0003422.g004
Figure 5. G-CSF-induced Stat3 activation is similar in WT and
K762R transfectants. BaF3 cells stably transfected with either the WT
G-CSFR or K762R/G-CSFR were washed and incubated in cytokine-free
media (RPMI/0.1%BSA) at 37uC for 4 hrs. Cells were then treated with G-
CSF (100 ng/ml) at 37uC for 10 min, washed, and incubated again in
cytokine-free media for the indicated times, then lysed. Proteins from
whole cell lysates were separated on SDS-PAGE and transferred onto
nitrocellulose membranes, which were blotted with anti-phospho-Stat3
antibody (upper panel). The blot was stripped and re-blotted with anti-
Stat3 antibody to confirm equal protein loading (lower panel). Cells
stimulated with activated orthovanadate at room temperature for
20 min are shown as a positive control.
doi:10.1371/journal.pone.0003422.g005
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that could serve as potential attachment sites for ubiquitin. The
lysine residue at position 762 is the sole cytoplasmic lysine that
localizes to the region that is deleted in the D716 G-CSFR mutant.
Recent studies by our laboratory have suggested that defective
ligand-induced ubiquitination of the D716 G-CSFR underlies its
aberrant internalization [20]. We were therefore interested in
determining whether site-specific disruption of ubiquitination at
lysine762 of the G-CSFR would induce a similar phenotype as the
D716 G-CSFR truncation mutant.
In the current study, we replaced the lysine residue at position
762 of the G-CSFR with an arginine residue, and examined the
effects of this mutation on G-CSF-mediated cellular responses and
signaling. CHO cells expressing the K762R/G-CSFR exhibited
markedly reduced mono- and polyubiquitination of the G-CSFR
in response to G-CSF compared to cells expressing the WT
receptor, indicating that lysine 762 is critical for ligand-induced G-
CSFR ubiquitination. BaF3 cells stably transfected with the
mutant K762R/G-CSFR were found to by hypersensitive to G-
CSF and could survive and proliferate in G-CSF concentrations as
low as 0.08 ng/ml, a concentration that was insufficient to support
the growth and survival of cells expressing the WT receptor.
Furthermore, at G-CSF concentrations high enough to support
the survival of cells expressing the WT G-CSFR, cells expressing
the K762R mutant G-CSFR hyperproliferated in response to G-
CSF, which was reproducible in three independent experiments
using three different K762R clones. Additionally, following
withdrawal of the BaF3 transfectants from G-CSF-containing
media, cells expressing the K762R/G-CSFR mutant exhibited
prolonged survival over WT G-CSFR-expressing cells. These
results suggest that ubiquitination of the G-CSFR at lysine 762 is
required for the normal G-CSFR-mediated cell growth and
survival.
To confirm the physiologic relevance of our findings in BaF3
cells, we next examined the G-CSF-responsiveness of myeloid cells
expressing the K762R mutant. For these experiments, we used the
32Dcl3 cell line. 32Dcl3 cells stably expressing the K762R/G-
CSFR mutant also hyperproliferated in response to G-CSF and
exhibited enhanced survival following cytokine depletion. These
findings are consistent with our previously reported observations
with cells expressing the D716-G-CSFR [10], and suggest that
defective ubiquitination contributes to the aberrant cellular
response of cells from patients with SCN/AML to G-CSF.
Previous studies have demonstrated that both Stat3 and Stat5
are rapidly activated and phosphorylated in response to G-CSF
[34]. We were therefore interested in determining whether
mutation of lysine 762 which disrupts ligand-induced ubiquitina-
tion of the G-CSFR had any effect on Stat3 and Stat5 activation.
Notably, cells expressing the K762R/G-CSFR exhibited increased
activation of Stat5 in response to G-CSF compared to WT cells,
and Stat5 activation remained prolonged in K762R-expressing
cells even following G-CSF withdrawal. In contrast, there was no
evidence that activation of Stat3 was altered in K762/G-CSFR-
expressing cells. These findings are consistent with recently
published data from Link’s group in which expression of a
truncated mutant murine G-CSFR form (d715F) in mice that is
equivalent to the D716 human G-CSFR in patients with SCN/
AML was found to confer a strong clonal advantage that was
dependent on Stat5, but not Stat3 [35]. Importantly, Stat5 has
been implicated in leukemogenesis, and expression of constitu-
tively active Stat5 in hematopoietic cells has been shown to induce
a rapidly fatal myeloproliferative disease in mice [36–38].
A recent study by Irandoust et al in which all five lysine residues
in the G-CSFR were mutated to arginine was reported to result in
hyperproliferative responses to G-CSF [34]. These authors also
reported that cells expressing the lysine-deficient G-CSFR
exhibited prolonged activation of not only Stat5 but Stat3 as well.
The reasons for the differences in their results and those reported
here are not clear. However, collectively the results suggest that
the proximal four lysine residues in the G-CSFR may play roles in
Stat3 activation while lysine 762 is critical for Stat5 signaling,
implicating distinct roles for individual cytoplasmic lysine residues
in the G-CSFR.
Activation of the Akt signaling pathway has been reported to
protect a variety of cell types from apoptosis [10]. G-CSF has been
shown to induce rapid phosphorylation of Akt at serine 473 in
both WT- and D716 G-CSFR-expressing cells. Moreover, we have
previously reported that the enzymatic activity of Akt in response
to G-CSF is prolonged in cells expressing the D716 G-CSFR [10].
Our current results also demonstrate enhanced and prolonged
activation of Akt in K762R-expressing cells in response to G-CSF
compared to WT cells, suggesting that ubiquitination is also
involved in regulation of the Akt signaling pathway in response to
G-CSF stimulation.
Collectively, our data suggest a role for ubiquitination in G-
CSF-mediated cell survival and proliferation. Lysine 762 in the
Figure 6. Prolonged Akt activation in response to G-CSF in BaF3 cells transfected with the K762R/G-CSFR. BaF3 cells stably transfected
with either the WT G-CSFR or K762R/G-CSFR were washed and incubated in cytokine-free media (RPMI/0.1%BSA) at 37uC for 4 hrs. Cells were then
treated with G-CSF (100 ng/ml) at 37uC for 10 min, washed, incubated in cytokine-free media again for the indicated times, and lysed. Whole cell
lysates were immunoprecipitated with anti-Akt antibody, and blotted with anti-phospho-Ser-Akt antibody (upper panel). The blot was stripped and
re-blotted with anti-Akt antibody to confirm equal protein loading (lower panel). Cells stimulated with activated orthovanadate at room temperature
for 20 min are shown as a positive control.
doi:10.1371/journal.pone.0003422.g006
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the amplitude and duration of Stat5 and Akt activation. Future
studies to identify the molecules that interact with the ubiquiti-
nated G-CSFR and the E3 ligase that is recruited to the
phosphorylated G-CSFR should provide additional insights into
the mechanisms that downregulate G-CSFR signaling, which are
disrupted in patients with SCN/AML.
Materials and Methods
Reagents and cell culture
G-CSF-responsive murine 32Dcl3 cells were kindly provided by
Dr. Giovanni Rovera (The Wistar Institute, Philadelphia, PA,
USA) and were maintained in RPMI-1640 medium supplemented
with 10% fetal bovine serum (FBS) and 10% WEHI 3B
conditioned medium as a source of IL-3. BaF3 cells were
maintained in RPMI 1640 medium supplemented with 2 mM
glutamine, 10% FBS, and 10% WEHI-3B conditioned media as a
source of interleukin 3 (IL-3). Chinese hamster ovary (CHO) cells
were grown in aMEM (aMinimum Essential Media) supplement-
ed with 4.5 g/L glucose and 10% FBS. Penicillin and streptomy-
cin (100 U/mL each) were added to all culture media.
Recombinant human G-CSF was a generous gift from Amgen
(Thousand Oaks, CA). Media and cell culture reagents were
purchased from GIBCO/Invitrogen (Carlsbad, CA).
Plasmid construction and transfection
The wild type G-CSFR (WT G-CSFR) cDNA was cloned into
the pcDNA3.1D-TOPO mammalian expression vector (Invitro-
gen) in frame with a V5 epitope tag, as described previously [39].
QuikChangeH II Site-Directed Mutagenesis Kit was purchased
from Stratagene (La jolla, CA), and the K762R/G-CSFR mutant
was generated according to the protocol provided with the kit.
Briefly, using the WT G-CSFR plasmid as a template, PCR
reactions were performed with an initial 30-second denaturation at
95uC, followed by 14 cycles of denaturation at 95uC for
30 seconds, annealing at 55uC for 1 minute, and elongation at
68uC for 8 minutes, and a final digestion by DpnI for 1 hour at
37uC. The forward primer was 59-CCCCAGCCCCAGGTCC-
TATGAGAACCTC-39, and the reverse primer was 59-
GAGGTTCTCATAGGACCTGGGGCTGGGG-39. The
K762R/G-CSFR was also epitope-tagged with V5. The fidelity
of the entire open reading frame of each expression vector was
confirmed by automated DNA sequencing. The hemagluttinin
(HA)-tagged ubiquitin cDNA was generously provided by Dr. Dirk
Bohmann (University of Rochester, Rochester, NY).
BaF3 cells were stably transfected with the various G-CSFR
forms using conditions that have previously been described [40].
Single clones were isolated by limiting dilution and screened by
immunoblotting. A pool of three single clones with similar
expression levels was used in the experiments. Stable transfection
of 32Dcl3 cells was described previously [41]. Transient
transfection of CHO cells was performed in 60 mm dishes using
Effectene reagent (Qiagen, Valencia, CA) according to the
manufacturer’s instructions.
Cell viability and proliferation
Stably transfected BaF3 and 32Dcl3 cells (WT and K762R
mixed-pools) were removed from IL-3-containing media, washed,
and then grown in the presence of 10 ng/ml of G-CSF at 37uC
overnight. Cells were then washed and resuspended in cytokine-
free media and incubated at 37uC for 0 h, 4 h, 8 h, 12 h, and
24 h. At each time point, 5610
3 cells were removed and analyzed
using the CellTiter-Glo Cell Viability Luminescence Assay
protocol (Promega, Madison, WI) utilizing the Berthold Technol-
ogies Centro XS
3 LB 960 plate luminometer and MicroWin 2000
software. Cells were also counted at each time point and cell
viability was determined by Trypan Blue staining. For prolifera-
tion experiments, cells were grown in different concentrations of
G-CSF for 72 h to determine their dose response to G-CSF.
Aliquots of cells were subsequently grown in 2 ng/ml of G-CSF
for either 72 h (32Dcl3 cells) or 18 days (BaF3 cells) and cell
numbers counted at each time point.
Antibodies, immunoprecipitations and immunoblot
analysis
Antibody to V5 was purchased from Invitrogen (Carlsbad, CA).
Anti-poly/monoubiquitin antibody raised against the FK2 clone
was purchased from Affiniti Research (Exeter, UK). Antibodies to
phospho-Stat3 (pStat3), phospho-Stat5 (pStat5), and phospho-
serine-Akt (pSerAkt) were purchased from Cell Signal (Danvers,
MA). Antibodies to Stat3, Stat5, Akt, and actin were from Santa
Cruz (Santa Cruz, CA).
Cells (2610
7/mL) were lysed in ice-cold lysis buffer (1.5%
Triton X-100, 0.1% Sodium Dodecyl Sulfate (SDS), 0.1 mM
sodium deoxycholate, 500 mM NaCl, 5 mM EDTA, 10 mM N-
ethylmaleimide, 25 mM HEPES, pH 7.8) containing a cocktail of
protease inhibitors (Roche, Indianapolis, IN), incubated on ice for
20 min, and centrifuged at 4uC at 10,000 g. The supernatants
were collected from each sample and protein concentrations
determined using the BCA reagent (Pierce, Rockford, IL). A total
of 400 mg of protein from each sample in equivalent final volumes
was mixed 1:1 with IP buffer (10% glycerol, 100 mM KCl, 5 mM
MgCl2, 50 mM Tris, pH 8), and incubated with 1–2 mg antibodies
and 30 mL of protein G-agarose (Invitrogen) overnight at 4uC.
Immunoprecipitates were collected by centrifugation at 2,000 g at
4uC, washed 36 with a 1:1 mix of lysis and IP buffers, and
resuspended in LDS sample buffer (Invitrogen). The samples were
heated to 70uC for 10 min, resolved on 4–12% Bis-Tris
acrylamide gels using a MOPS running buffer (Invitrogen), and
transferred to nitrocellulose. For analysis of whole cell lysates, 20–
80 mg of protein from each sample was resolved by SDS-PAGE
and subjected to immunoblot analysis. Immunoreactive bands
were visualized using the enhanced chemiluminescence (ECL)
reagent (Amersham, Piscataway, NJ). For densitometric analysis,
ImageJ software made available through the National Institutes of
Health was used.
For analysis of G-CSFR ubiquitination in cells transiently co-
expressing HA-tagged ubiquitin and either the WT G-GSFR or
the K762R/G-CSFR, CHO cells were transferred 48 h after
cotransfections to serum-free MEMa media (containing 20 mM
HEPES, penicillin/streptomycin, 4.5 gm/L glucose, and 1% BSA)
for 4 h at 4uC, and incubated with 100 ng/mL G-CSF at 37uC for
varying times. For signaling studies, cells were washed and
incubated in serum-free media (RPMI/0.1%BSA) devoid of all
cytokines and incubated at 37uC for 4 hours. Cells were then
treated with G-CSF (100 ng/ml) at 37uC for 10 min, washed,
incubated in serum and cytokine-free media for varying times, and
lysed. Aliquots of cells were stimulated with activated orthovana-
date (5 ml/100 ml cell suspension) at room temperature for 20 min
as a positive control. Cell lysis, immunoprecipitations and
immunoblotting were performed as described above.
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